Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Boceprevir

FDA-approved product (capsule, oral), marketed as Victrelis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Boceprevir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis C virus infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antivirals for treatment of hcv infections
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AP03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis51.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Boceprevir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Boceprevir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

    NCT01465516 · start 2011-11

    Registered record
    Registry ID
    NCT01465516
    Conditions
    Hepatitis C Infection
    Interventions
    Boceprevir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2011-11
    Completion
    2013-12
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Infection
    InterventionBoceprevir
    PhaseNot recorded
    Registry statusTerminated

  • A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

    NCT01482403 · start 2011-11

    Registered record
    Registry ID
    NCT01482403
    Conditions
    Hepatitis C, Chronic
    Interventions
    Copegus; Copegus; Pegasys; Pegasys; boceprevir; boceprevir; mericitabine; mericitabine placebo; boceprevir placebo; boceprevir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-01
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionCopegus; Copegus; Pegasys; Pegasys +6 more
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)

    NCT01390844 · start 2011-10-21

    Registered record
    Registry ID
    NCT01390844
    Conditions
    Hepatitis C, Chronic
    Interventions
    Boceprevir (BOC); Placebo to boceprevir; Peginterferon alfa-2b (PEG); Ribavirin (RBV); Cross-Over Boceprevir Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-10-21
    Completion
    2015-06-19
    Enrolment
    282

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBoceprevir (BOC); Placebo to boceprevir; Peginterferon alfa-2b (PEG); Ribavirin (RBV) +1 more
    PhasePhase 3
    Registry statusCompleted

  • Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

    NCT01471717 · start 2011-10

    Registered record
    Registry ID
    NCT01471717
    Conditions
    Healthy
    Interventions
    INX-08189 50 mg QD X 5 days; INX-08189 / Victrelis 800 mg TID X three days; Victrelis 800 mg TID x 3 days; Victrelis 800 mg TID with INX-08189 50 mg QD; Placebo with Victrelis 800 mg; Cohort 2: Victrelis 800 mg with Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2011-10
    Completion
    2011-11
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionINX-08189 50 mg QD X 5 days; INX-08189 / Victrelis 800 mg TID X three days; Victrelis 800 mg TID x 3 days; Victrelis 800 mg TID with INX-08189 50 mg QD +2 more
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)

    NCT01396005 · start 2011-09

    Registered record
    Registry ID
    NCT01396005
    Conditions
    Hepatitis C Virus
    Interventions
    boceprevir; methadone; buprenorphine/naloxone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2011-12
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C Virus
    Interventionboceprevir; methadone; buprenorphine/naloxone
    PhasePhase 1
    Registry statusCompleted

  • Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

    NCT01443923 · start 2011-09

    Registered record
    Registry ID
    NCT01443923
    Conditions
    Hepatitis; HIV/AIDS
    Interventions
    Boceprevir; Peg-Interferon-alfa 2B; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2013-09
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis; HIV/AIDS
    InterventionBoceprevir; Peg-Interferon-alfa 2B; Ribavirin
    PhasePhase 4
    Registry statusTerminated

  • Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir

    NCT02113631 · start 2011-09

    Registered record
    Registry ID
    NCT02113631
    Conditions
    Hepatitis C, Chronic; Cirrhosis
    Interventions
    Telaprevir; Boceprevir; Peg-IFN; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-09
    Completion
    2013-04
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic; Cirrhosis
    InterventionTelaprevir; Boceprevir; Peg-IFN; Ribavirin
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

    NCT01288417 · start 2011-08

    Registered record
    Registry ID
    NCT01288417
    Conditions
    HIV Infections; HCV Infections
    Interventions
    boceprevir; raltegravir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; HCV Infections
    Interventionboceprevir; raltegravir
    PhasePhase 1
    Registry statusCompleted

  • Potential for Drug-drug Interactions Between Boceprevir and Etravirine in HIV/Hepatitis C Virus Negative Volunteers

    NCT01427504 · start 2011-08

    Registered record
    Registry ID
    NCT01427504
    Conditions
    Hepatitis C; HIV
    Interventions
    boceprevir; etravirine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-08
    Completion
    2012-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C; HIV
    Interventionboceprevir; etravirine
    PhaseNot applicable
    Registry statusCompleted

  • Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)

    NCT01353911 · start 2011-06-27

    Registered record
    Registry ID
    NCT01353911
    Conditions
    Hepatitis C, Chronic
    Interventions
    Grazoprevir; Boceprevir; Placebo for Grazoprevir; Placebo for Boceprevir; Peg-interferon alfa-2b; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-06-27
    Completion
    2015-03-10
    Enrolment
    368

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionGrazoprevir; Boceprevir; Placebo for Grazoprevir; Placebo for Boceprevir +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

    NCT01359644 · start 2011-06

    Registered record
    Registry ID
    NCT01359644
    Conditions
    Chronic Hepatitis C
    Interventions
    PSI-7977; Daclatasvir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-06
    Completion
    2013-10
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionPSI-7977; Daclatasvir; Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • Boceprevir in HIV-HCV Coinfected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin

    NCT01335529 · start 2011-05

    Registered record
    Registry ID
    NCT01335529
    Conditions
    HCV Coinfection; HIV-1 Infection
    Interventions
    Boceprevir, Peg-interferon alfa 2b and Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-05
    Completion
    2014-05
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHCV Coinfection; HIV-1 Infection
    InterventionBoceprevir, Peg-interferon alfa 2b and Ribavirin
    PhasePhase 2
    Registry statusCompleted

  • French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin

    NCT01514890 · start 2011-02

    Registered record
    Registry ID
    NCT01514890
    Conditions
    Chronic Hepatitis C
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-02
    Completion
    2014-03
    Enrolment
    675

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Impact of Antiviral Therapy on Gastroesophageal Varices.

    NCT02758509 · start 2010-01-01

    Registered record
    Registry ID
    NCT02758509
    Conditions
    Chronic Hepatitis C; Cirrhosis
    Interventions
    Pegylated interferon alfa-2a + Ribavirin; Pegylated interferon alfa-2a + Ribavirin + Boceprevir; Pegylated interferon alfa-2a + Ribavirin +Telaprevir; Ledipasvir/Sofosbuvir; Ombitasvir/paritaprevir/ritonavir+Dasabuvir; Daclatasvir+Sofosbuvir; Simeprevir+Sofosbuvir
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-01-01
    Completion
    2017-10-15
    Enrolment
    237

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Hepatitis C; Cirrhosis
    InterventionPegylated interferon alfa-2a + Ribavirin; Pegylated interferon alfa-2a + Ribavirin + Boceprevir; Pegylated interferon alfa-2a + Ribavirin +Telaprevir; Ledipasvir/Sofosbuvir +3 more
    PhaseNot recorded
    Registry statusCompleted

  • Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)

    NCT00910624 · start 2009-06-22

    Registered record
    Registry ID
    NCT00910624
    Conditions
    Hepatitis C, Chronic
    Interventions
    Boceprevir; Peginterferon alfa-2b (SCH 54031); Ribavirin (SCH 18908)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06-22
    Completion
    2012-12-07
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C, Chronic
    InterventionBoceprevir; Peginterferon alfa-2b (SCH 54031); Ribavirin (SCH 18908)
    PhasePhase 3
    Registry statusCompleted